[ET Net News Agency, 24 September 2021] Credit Suisse kept its target price for Everest
Med (01952) at HK$80 and maintained its "outperform" rating.
The research house said it maintains the "outperform" rating given Everest's active BD
deal performance in the past month and the encouraging potential the BD deals have brought
in. (RC)